Dabco → 5-chloro-2,4-difluoro-N-pyrimidin-4-ylbenzenesulfonamide

HRID 46363

Reaction equation

HRID 46363 reaction equation
[NH2:1][C:2]1[CH:7]=[CH:6][N:5]=[CH:4][N:3]=1.N12CCN(CC1)CC2.[Cl:16][C:17]1[C:18]([F:28])=[CH:19][C:20]([F:27])=[C:21]([S:23](Cl)(=[O:25])=[O:24])[CH:22]=1>C(#N)C>[Cl:16][C:17]1[C:18]([F:28])=[CH:19][C:20]([F:27])=[C:21]([S:23]([NH:1][C:2]2[CH:7]=[CH:6][N:5]=[CH:4][N:3]=2)(=[O:25])=[O:24])[CH:22]=1

Participants

5

Procedure

A mixture of 4-aminopyrimidine (1.30 g, 13.7 mmol) and 1,4-diazabicyclo[2.2.2]octane (1.54 g, 13.7 mmol) were added concurrently to a solution of 5-chloro-2,4-difluorobenzenesulfonyl chloride (3.4 g, 14 mmol) in anhydrous acetonitrile (63 mL). The reaction mixture immediately turned yellow and a precipitate formed. The reaction mixture was stirred under argon. After 72 hours, the reaction mixture was filtered and the filtrate was concentrated in vacuo to give a residue. The residue was partitioned between 1M hydrochloric acid and ethyl acetate. The organic phase was separated, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was partially purified by automated flash column chromatography using an 80 g silica gel ISCO™ column using hexanes to 1% v/v acetic acid in ethyl acetate gradient elution. The product was purified a second time by reverse phase HPLC to give the title compound (193 mg, 5%) as a white solid.

Workup

  1. customThe reaction mixture immediately turned yellow and a precipitate formed
  2. filtrationthe reaction mixture was filtered
  3. concentrationthe filtrate was concentrated in vacuo
  4. customto give a residue
  5. customThe residue was partitioned between 1M hydrochloric acid and ethyl acetate
  6. customThe organic phase was separated
  7. dry with materialdried over anhydrous magnesium sulfate
  8. concentrationconcentrated in vacuo
  9. customThe residue was partially purified by automated flash column chromatography
  10. washto 1% v/v acetic acid in ethyl acetate gradient elution
  11. customThe product was purified a second time by reverse phase HPLC

Sources & evidence

ORD record
ord-e411c3715dc34aff853b7427251500dc
Source dataset
uspto-grants-2013_09
Patent number
US08541588B2

Linked notes

Loading…